Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML

Last updated: December 29, 2025
Sponsor: Peking University People's Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Leukemia

Lymphoproliferative Disorders

Acute Myeloid Leukemia

Treatment

MFC for the determination of leukemia stem cell

Clinical Study ID

NCT06452732
PekingUPH Chang Ying-Jun
  • Ages < 18
  • All Genders

Study Summary

Leukaemia is a major disease that seriously endangers human health, the long-term survival rate of acute myeloid leukaemia receiving conventional chemotherapy is only 10% to 45%, haematological relapse is the main cause of treatment failure in acute myeloid leukaemia, reducing the relapse rate is the key to improving the efficacy of acute leukaemia, biomarker-guided preemptive therapy is an effective way to reduce the recurrence of leukaemia, existing markers to predict the recurrence has a high false Existing markers have high false-negative and false-positive rates for predicting relapse, and improving the accuracy of leukaemia relapse prediction is a major clinical problem that needs to be solved urgently. The group has found that circulating leukaemia stem cells remaining after chemotherapy are the key to relapse, therefore, we propose to conduct a multicentre prospective clinical study on the prediction of acute leukaemia relapse by circulating leukaemia stem cells.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Newly diagnoses candidates with acute myeloid leukemia.

  • Lower than or equal to 18 years-old;

  • Subjects are able to provide written informed consent.

Exclusion

Exclusion Criteria:

  • Subjects who cannot comply with the study;

  • Subjects with severe cardiac disease (ejection fraction<50% ), liver disease (totalbilirubin >34umol/L, ALT and AST>1.5×upper limit normal) or kidney disease (Serumcreatinine>130umol/L).

  • Subjects with severe infection.

  • Subjects with other conditions that cannot receive chemotherapy or transplantation.

Study Design

Total Participants: 283
Treatment Group(s): 1
Primary Treatment: MFC for the determination of leukemia stem cell
Phase:
Study Start date:
November 01, 2024
Estimated Completion Date:
June 30, 2026

Connect with a study center

  • Peking University People's Hospital

    Beijing, Beijing 100044
    China

    Active - Recruiting

  • People's Hospital of Peking University

    Beijing, Beijing 100044
    China

    Site Not Available

  • Peking University People's Hospital

    Beijing 1816670, Beijing Municipality 2038349 100044
    China

    Active - Recruiting

  • People's Hospital of Peking University

    Beijing 1816670, Beijing Municipality 2038349 100044
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.